On Oct 31, major Wall Street analysts update their ratings for $Exelixis (EXEL.US)$, with price targets ranging from $29 to $38.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $30.
BofA Securities analyst Jason Gerberry maintains with a buy rating.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $31 to $38.
Wells Fargo analyst Derek Archila maintains with a buy rating, and adjusts the target price from $32 to $36.
TD Cowen analyst Yaron Werber maintains with a buy rating, and maintains the target price at $34.
Furthermore, according to the comprehensive report, the opinions of $Exelixis (EXEL.US)$'s main analysts recently are as follows:
Exelixis' third quarter showed robust performance for Cabometyx, with net product sales exceeding expectations by approximately 8% and achieving 12% growth compared to the previous year. The consistent revenue generation from Cabometyx and the promising prospects of the pipeline, particularly through zanzalintinib, are seen as significant potential contributors to future performance.
Exelixis' third-quarter cabo revenues surpassed expectations, coming in at $478.1 million, which reflects a 4.7% beat over the consensus. This performance is attributed to an uptick in cabo market share and an increase in new patient starts. Concurrently, the management has revised its future net product revenue and total revenue guidance upwards by 5.6% and 7.4% respectively. Despite this positive outlook, a cautious stance is maintained regarding zanza until further late-stage data is available to justify increased estimates.
Here are the latest investment ratings and price targets for $Exelixis (EXEL.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$伊克力西斯 (EXEL.US)$的評級，目標價介於29美元至38美元。
摩根士丹利分析師Jeffrey Hung維持持有評級，維持目標價30美元。
美銀證券分析師Jason Gerberry維持買入評級。
花旗分析師David Lebowitz維持買入評級，並將目標價從31美元上調至38美元。
富國集團分析師Derek Archila維持買入評級，並將目標價從32美元上調至36美元。
TD Cowen分析師Yaron Werber維持買入評級，維持目標價34美元。
此外，綜合報道，$伊克力西斯 (EXEL.US)$近期主要分析師觀點如下：
伊克力西斯第三季度Cabometyx表現強勁，淨產品銷售額超出預期約8％，與去年相比增長12％。Cabometyx持續的營業收入和具有潛在前景的管道，特別是zanzalintinib，被視爲未來業績的重要潛在貢獻者。
伊克力西斯第三季度Cabometyx收入超出預期，達到47810萬美元，比一致預期高出4.7％。這一業績歸因於Cabometyx市場份額的提升和新患者增加。同時，管理層已將未來淨產品收入和總營收預測分別上調了5.6％和7.4％。儘管展望積極，但對zanza仍保持謹慎態度，直到有更多後期數據可用以證明增加的估計。
以下爲今日10位分析師對$伊克力西斯 (EXEL.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
